Measles and its neurological complications

Clinical Neurovirology

Volumn , Issue , 2003, Pages 401-430

  Weissbrich, Benedikt ^a   Schneider Schaulies, Jürgen ^a   Ter Meulen, Volker ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858629273     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (146)

1. ter Meulen, V.; Billeter, M.A. Measles Virus. Volume 191 of Current Topics in Microbiology and Immunology; Capron, A., Compans, R.W., Cooper, M., Koprowski, H., McConnell, I., Melchers, F., Oldstone, M., Olsnes, S., Potter, M., Saedler, H., Vogt, P.K., Wagner, H., Wilson, I., Eds.; Springer-Verlag: New York, 1995.
2. Schneider-Schaulies, S.; ter Meulen, V. Measles. In Principles and Practice of Clinical Virology; Zuckerman, A.J., Banatvala, J.E., Pattison, J.R., Eds.; Wiley: Chichester, 2000, 357–386.
3. Duclos, P.; Ward, B.J. Measles vaccines: a review of adverse events. Drug Saf. 1998, 19, 435–454.
4. Radecke, F.; Billeter, M.A. Measles virus antigenome and protein consensus sequences. In Measles Virus; Billeter, M.A., ter Meulen, V., Eds.; Springer-Verlag: New York, 1995, 181–192.
5. Liston, P.; Briedis, D.J. Ribosomal frameshifting during translation of measles virus P protein mRNA is capable of directing synthesis of a unique protein. J Virol. 1995, 69, 6742–6750.
6. Parks, C.L.; Lerch, R.A.; Walpita, P.; Wang, H.P.; Sidhu, M.S.; Udem, S.A. Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage. J Virol. 2001, 75, 921–933.
7. Dörig, R.E.; Marcil, A.; Chopra, A.; Richardson, C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993, 75, 295–305.
8. Naniche, D.; Varior-Krishnan, G.; Cervoni, F.; Wild, T.F.; Rossi, B.; Rabourdin-Combe, C.; Gerlier, D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993, 67, 6025–6032.
9. Tatsuo, H.; Ono, N.; Tanaka, K.; Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000, 406, 893–897.
10. Erlenhoefer, C.; Wurzer, W.J.; Löffler, S.; Schneider-Schauliesxy, S.; ter Meulen, V.; Schneider-Schaulies, J. CD150 (SLAM) is a receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition. J Virol. 2001, 75, 4499–4505.
11. Rota, J.S.; Hummel, K.B.; Rota, P.A.; Bellini, W.J. Genetic variability of the glycoprotein genes of current wild-type measles isolates. Virology. 1992, 188, 135–142.
12. Rima, B.K.; Earle, J.A.; Baczko, K.; ter Meulen, V.; Liebert, U.G.; Carstens, C.; Carabana, J.; Caballero, M.; Celma, M.L.; Fernandez-Munoz, R. Sequence divergence of measles virus haemagglutinin during natural evolution and adaptation to cell culture. J Gen Virol. 1997, 78, 97–106.
13. World Health Organization. Nomenclature for describing the genetic characteristics of wildtype measles viruses (update). Part I. Wkly Epidemiol Rec. 2001, 76, 242–247.
14. World Health Organization. Nomenclature for describing the genetic characteristics of wildtype measles viruses (update). Wkly Epidemiol Rec. 2001, 76, 249–251.
15. Bellini, W.J.; Rota, P.A. Genetic diversity of wild-type measles viruses: implications for global measles elimination programs. Emerg Infect Dis. 1998, 4, 29–35.
16. Greenhill, W.A. A Treatise on the Smallpox and Measles. (Translated from the original Arabic); Sydenham Society: London, 1848.
17. Goldberger, J.; Anderson, J.F. An experimental demonstration of the presence of the virus of measles in the mixed buccal and nasal secretions. JAMA. 1911, 57, 476–478.
18. Enders, J.F.; Peebles, T.C. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med. 1954, 36, 277–286.
19. Centers for Disease Control and Prevention. Global measles control and regional elimination, 1998–1999. MMWR; 1999; Vol. 48, 1124–1130.
20. Landrigan, P.J.; Witte, J.J. Neurologic disorders following live measles-virus vaccination. JAMA. 1973, 223, 1459–1462.
21. Polack, F.P.; Auwaerter, P.G.; Lee, S.H.; Nousari, H.C.; Valsamakis, A.; Leiferman, K.M.; Diwan, A.; Adams, R.J.; Griffin, D.E. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med. 1999, 5, 629–634.
22. Ojala, A. On changes in the cerebrospinal fluid during measles. Ann Med Intern Fenn. 1947, 36, 321–331.
23. Gibbs, F.A.; Gibbs, E.L.; Carpenter, P.R.; Spies, H.W. Electroencephalographic abnormality in “uncomplicated” childhood diseases. JAMA. 1959, 171, 1050–1055.
24. Hanninen, P.; Arstila, P.; Lang, H.; Salmi, A.; Panelius, M. Involvement of the central nervous system in acute, uncomplicated measles virus infection. J Clin Microbiol. 1980, 11, 610–613.
25. Griffin, D.E.; Hemachudha, T.; Johnson, R.T. Postinfectious and postvaccinal encephalomyelitis. In Clinical and Molecular Aspects of Neurotropic Virus Infection; Gilden, D.H., Lipton, H.L., Eds.; Kluwer Academic: Boston, 1989, 501–527.
26. Meyer, E.; Byers, R.K. Measles encephalitis. Am J Dis Child. 1952, 84, 543–579.
27. Johnson, R.T.; Griffin, D.E.; Hirsch, R.L.; Wolinsky, J.S.; Roedenbeck, S.; Lindo de Soriano, I.; Vaisberg, A. Measles encephalomyelitis—clinical and immunologic studies. N Engl J Med. 1984, 310, 137–141.
28. von Pirquet, C. Das Verhalten der kutanen Tuberkulin-Reaktion während der Masern. Dtsch Med Wochenschr. 1908, 34, 1297–1300.
29. Sanchez-Lanier, M.; Guerin, P.; McLaren, L.C.; Bankhurst, A.D. Measles virus-induced suppression of lymphocyte proliferation. Cell Immunol. 1988, 116, 367–381.
30. Borrow, P.; Oldstone, M.B.A. Measles virus–mononuclear cell interactions. In: Measles Virus; Billeter, M.A., ter Meulen, V., Eds.; Springer-Verlag: New York, 1995, 85–100.
31. Schlender, J.; Schnorr, J.J.; Spielhoffer, P.; Cathomen, T.; Cattaneo, R.; Billeter, M.A.; ter Meulen, V.; Schneider-Schaulies, S. Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro. Proc Natl Acad Sci USA. 1996, 93, 13194–13199.
32. Fujinami, R.S.; Sun, X.; Howell, J.M.; Jenkin, J.C.; Burns, J.B. Modulation of immune system function by measles virus infection: role of soluble factor and direct infection. J Virol. 1998, 72, 9421–9427.
33. Karp, C.L.; Wysocka, M.; Wahl, L.M.; Ahearn, J.M.; Cuomo, P.J.; Sherry, B.; Trinchieri, G.; Griffin, D.E. Mechanism of suppression of cell-mediated immunity by measles virus. Science. 1996, 273(5303), 228–231.
34. Avota, E.; Avots, A.; Niewiesk, S.; Kane, L.P.; Bommhardt, U.; ter Meulen, V.; Schneider- Schaulies, S. Disruption of Akt kinase activation is important for immunosuppression induced by measles virus. Nat Med. 2001, 7, 725–731.
35. Schnorr, J.J.; Seufert, M.; Schlender, J.; Borst, J.; Johnston, I.C.; ter Meulen, V.; Schneider- Schaulies, S. Cell cycle arrest rather than apoptosis is associated with measles virus contactmediated immunosuppression in vitro. J Gen Virol. 1997, 78, 3217–3226.
36. Steineur, M.P.; Grosjean, I.; Bella, C.; Kaiserlian, D. Langerhans cells are susceptible to measles virus infection and actively suppress T cell proliferation. Eur J Dermatol. 1998, 8, 413–420.
37. Klagge, I.M.; Schneider-Schaulies, S. Virus interactions with dendritic cells. J Gen Virol. 1999, 80, 823–833.
38. Gendelman, H.E.; Wolinsky, J.S.; Johnson, R.T.; Pressman, N.J.; Pezeshkpour, G.H.; Boisset, G.F. Measles encephalomyelitis: lack of evidence of viral invasion of the central nervous system and quantitative study of the nature of demyelination. Ann Neurol. 1984, 15, 353–360.
39. Moench, T.R.; Griffin, D.E.; Obriecht, C.R.; Vaisberg, A.J.; Johnson, R.T. Acute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA. J Infect Dis. 1988, 158, 433–442.
40. Johnson, R.T. The pathogenesis of acute viral encephalitis and postinfectious encephalomyelitis. J Infect Dis. 1987, 155, 359–364.
41. Moench, T.R.; Johnson, R.T. Measles. In Clinical and Molecular Aspects of Neurotropic Virus Infection; Gilden, D.H., Lipton, H.L., Eds.; Kluwer Academic: Boston, 1989, 201–229.
42. Caceres, V.M.; Strebel, P.M.; Sutter, R.W. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis. 2000, 31, 110–119.
43. Albrecht, P.; Ennis, F.A.; Saltzman, E.J.; Krugman, S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977, 91, 715–718.
44. Schlereth, B.; Rose, J.K.; Buonocore, L.; ter Meulen, V.; Niewiesk, S. Successful vaccineinduced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol. 2000, 74, 4652–4657.
45. Davidkin, I.; Valle, M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine. 1998, 16, 2052–2057.
46. Davidkin, I.; Valle, M.; Peltola, H.; Hovi, T.; Paunio, M.; Roivainen, M.; Linnavuori, K.; Jokinen, S.; Leinikki, P. Etiology of measles- and rubella-like illnesses in measles, mumps, and rubella-vaccinated children. J Infect Dis. 1998, 178, 1567–1570.
47. Mitchell, C.D.; Balfour, H.H., Jr. Measles control: so near and yet so far. Prog Med Virol. 1985, 31, 1–42.
48. Orenstein, W.A.; Strebel, P.M.; Papania, M.; Sutter, R.W.; Bellini, W.J.; Cochi, S.L. Measles eradication: is it in our future?. Am J Public Health. 2000, 90, 1521–1525.
49. Dawson, J.R.J. Cellular inclusions in cerebral lesions of lethargic encephalitis. Am J Pathol. 1933, 9, 7.
50. Dawson, J.R.J. Cellular inclusions in cerebral lesions of epidemic encephalitis. Arch Neurol Psychiatry. 1934, 31, 685–700.
51. Pette, H.; Döring, G. Über einheimische Panencephalomyelitis vom Charakter der Encephalitis japonica. Dtsch Z Nervenheilkd. 1939, 149, 7–44.
52. van Bogaert, L. Une leuco-encéphálite sclérosante suaigü. J Neurol Neurosurg Psychiatry. 1945, 8, 101.
53. Greenfield, J.G. Encephalitis and encephalomyelitis in England and Wales during the last decade. Brain. 1950, 73, 141–166.
54. Bouteille, M.; Fontaine, C.; Vedrenne, C.L.; Dalarue, J. Sur un cas de encéphalite suaigue a` inclusions: étude anatomoclinique et ultrastructurale. Rev Neurol (Paris). 1965, 118, 454–458.
55. Connolly, J.H.; Allen, I.V.; Hurwitz, L.J.; Millar, J.H. Measles-virus antibody and antigen in subacute sclerosing panencephalitis. Lancet. 1967, 1, 542–544.
56. Freeman, J.M.; Magoffin, R.L.; Lennette, E.H.; Herndon, R.M. Additional evidence of the relation between subacute inclusion-body encephalitis and measles virus. Lancet. 1967, 2, 129–131.
57. Horta-Barbosa, L.; Fuccillo, D.A.; Sever, J.L.; Zeman, W. Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy. Nature. 1969, 221, 974.
58. Payne, F.E.; Baublis, J.V.; Itabashi, H.H. Isolation of measles virus from cell cultures of brain from a patient with subacute sclerosing panencephalitis. N Engl J Med. 1969, 281, 585–589.
59. Haddad, F.S.; Risk, W.S.; Jabbour, J.T. Subacute sclerosing panencephalitis in the Middle East: report of 99 cases. Ann Neurol. 1977, 1, 211–217.
60. Dyken, P.R. Subacute sclerosing panencephalitis. Current status. Neurol Clin. 1985, 3, 179–196.
61. Singer, C.; Lang, A.E.; Suchowersky, O. Adult-onset subacute sclerosing panencephalitis: case reports and review of the literature. Mov Disord. 1997, 12, 342–353.
62. Gascon, G.G. Subacute sclerosing panencephalitis. Semin Pediatr Neurol. 1996, 3, 260–269.
63. Freeman, J.M. The clinical spectrum and early diagnosis of Dawson’s encephalitis, with preliminary notes on treatment. J Pediatr. 1969, 75, 590–603.
64. Jabbour, J.T.; Garcia, J.H.; Lemmi, H.; Ragland, J.; Duenas, D.A.; Sever, J.L. Subacute sclerosing panencephalitis. A multidisciplinary study of eight cases. JAMA. 1969, 207, 2248–2254.
65. Risk, W.S.; Haddad, F.S. The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East. Arch Neurol. 1979, 36, 610–614.
66. Gascon, G.; Yamani, S.; Crowell, J.; Stigsby, B.; Nester, M.; Kanaan, I.; Jallu, A. Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev. 1993, 15, 346–355.
67. Grunewald, T.; Lampe, J.; Weissbrich, B.; Reichmann, H. A 35-year-old bricklayer with hemimyoclonic jerks. Lancet. 1998, 351, 1926.
68. Esiri, M.M.; Oppenheimer, D.R.; Brownell, B.; Haire, M. Distribution of measles antigen and immunoglobulin-containing cells in the CNS in subacute sclerosing panencephalitis (SSPE) and atypical measles encephalitis. J Neurol Sci. 1982, 53, 29–43.
69. Kirk, J.; Zhou, A.L.; McQuaid, S.; Cosby, S.L.; Allen, I.V. Cerebral endothelial cell infection by measles virus in subacute sclerosing panencephalitis: ultrastructural and in situ hybridization evidence. Neuropathol Appl Neurobiol. 1991, 17, 289–297.
70. Allen, I.V.; McQuaid, S.; McMahon, J.; Kirk, J.; McConnell, R. The significance of measles virus antigen and genome distribution in the CNS in SSPE for mechanisms of viral spread and demyelination. J Neuropathol Exp Neurol. 1996, 55, 471–480.
71. Mesquita, R.; Castanos-Velez, E.; Biberfeld, P.; Troian, R.M.; de Siqueira, M.M. Measles virus antigen in macrophage/microglial cells and astrocytes of subacute sclerosing panencephalitis. APMIS. 1998, 106, 553–561.
72. ter Meulen, V.; Hall, W.W. Slow virus infections of the nervous system: virological, immunological and pathogenetic considerations. J Gen Virol. 1978, 41, 1–25.
73. ter Meulen, V.; Carter, M.J. Measles virus persistency and disease. Prog Med Virol. 1984, 30, 44–61.
74. Nakayama, T.; Mori, T.; Yamaguchi, S.; Sonoda, S.; Asamura, S.; Yamashita, R.; Takeuchi, Y.; Urano, T. Detection of measles virus genome directly from clinical samples by reverse transcriptase-polymerase chain reaction and genetic variability. Virus Res. 1995, 35, 1–16.
75. Katayama, Y.; Kohso, K.; Nishimura, A.; Tatsuno, Y.; Homma, M.; Hotta, H. Detection of measles virus mRNA from autopsied human tissues. J Clin Microbiol. 1998, 36, 299–301.
76. ter Meulen, V.; Stephenson, J.R.; Kreth, H.W. Subacute sclerosing panencephalitis. In Comprehensive Virology; Fraenkel-Conrat, H., Wagner, R.R., Eds.; Plenum Press: New York, 1983, 105–159.
77. Schneider-Schaulies, J.; Niewiesk, S.; Schneider-Schaulies, S.; ter Meulen, V. Measles virus in the CNS: the role of viral and host factors for the establishment and maintenance of a persistent infection. J Neurovirol. 1999, 5, 613–622.
78. Carter, M.J.; Willcocks, M.M.; ter Meulen, V. Defective translation of measles virus matrix protein in a subacute sclerosing panencephalitis cell line. Nature. 1983, 305, 153–155.
79. Baczko, K.; Liebert, U.G.; Billeter, M.; Cattaneo, R.; Budka, H.; ter Meulen, V. Expression of defective measles virus genes in brain tissues of patients with subacute sclerosing panencephalitis. J Virol. 1986, 59, 472–478.
80. Cattaneo, R.; Schmid, A.; Rebmann, G.; Baczko, K.; ter Meulen, V.; Bellini, W.J.; Rozenblatt, S.; Billeter, M.A. Accumulated measles virus mutations in a case of subacute sclerosing panencephalitis: interrupted matrix protein reading frame and transcription alteration. Virology. 1986, 154, 97–107.
81. Liebert, U.G.; Baczko, K.; Budka, H.; ter Meulen, V. Restricted expression of measles virus proteins in brains from cases of subacute sclerosing panencephalitis. J Gen Virol. 1986, 67, 2435–2444.
82. Cattaneo, R.; Rebmann, G.; Baczko, K.; ter Meulen, V.; Billeter, M.A. Altered ratios of measles virus transcripts in diseased human brains. Virology. 1987, 160, 523–526.
83. Schneider-Schaulies, S.; Schneider-Schaulies, J.; Schuster, A.; Bayer, M.; Pavlovic, J.; ter Meulen, V. Cell type-specific MxA-mediated inhibition of measles virus transcription in human brain cells. J Virol. 1994, 68, 6910–6917.
84. Cattaneo, R.; Schmid, A.; Eschle, D.; Baczko, K.; ter Meulen, V.; Billeter, M.A. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell. 1988, 55, 255–265.
85. Ogura, H.; Ayata, M.; Hayashi, K.; Seto, T.; Matsuoka, O.; Hattori, H.; Tanaka, K.; Tanaka, K.; Takano, Y.; Murata, R. Efficient isolation of subacute sclerosing panencephalitis virus from patient brains by reference to magnetic resonance and computed tomographic images. J Neurovirol. 1997, 3, 304–309.
86. Fujinami, R.S.; Oldstone, M.B. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature. 1979, 279, 529–530.
87. Schneider-Schaulies, S.; Liebert, U.G.; Segev, Y.; Rager-Zisman, B.; Wolfson, M.; ter Meulen, V. Antibody-dependent transcriptional regulation of measles virus in persistently infected neural cells. J Virol. 1992, 66, 5534–5541.
88. Hofman, F.M.; Hinton, D.R.; Baemayr, J.; Weil, M.; Merrill, J.E. Lymphokines and immunoregulatory molecules in subacute sclerosing panencephalitis. Clin Immunol Immunopathol. 1991, 58, 331–342.
89. Nagano, I.; Nakamura, S.; Yoshioka, M.; Kogure, K. Immunocytochemical analysis of the cellular infiltrate in brain lesions in subacute sclerosing panencephalitis. Neurology. 1991, 41, 1639–1642.
90. Mehta, P.D.; Kulczycki, J.; Mehta, S.P.; Sobczyk, W.; Coyle, P.K.; Sersen, E.A.; Wisniewski, H.M. Increased levels of beta 2-microglobulin, soluble interleukin-2 receptor, and soluble CD8 in patients with subacute sclerosing panencephalitis. Clin Immunol Immunopathol. 1992, 65, 53–59.
91. Dhib-Jalbut, S.; Jacobson, S.; McFarlin, D.E.; McFarland, H.F. Impaired human leukocyte antigen-restricted measles virus-specific cytotoxic T-cell response in subacute sclerosing panencephalitis. Ann Neurol. 1989, 25, 272–280.
92. Griffin, D.E. Immune responses during measles virus infection. In Measles Virus; Billeter, M.A., ter Meulen, V., Eds.; Springer-Verlag: New York, 1995, 117–134.
93. Hara, T.; Yamashita, S.; Aiba, H.; Nihei, K.; Koide, N.; Good, R.A.; Takeshita, K. Measles virus-specific T helper 1/T helper 2-cytokine production in subacute sclerosing panencephalitis. J Neurovirol. 2000, 6, 121–126.
94. Radermecker, J. Aspects électroéncephalographiques dans trois cas d’encéphalite subaigue. Acta Neurol Psychiatr Belg. 1949, 49, 222–232.
95. Dogulu, C.F.; Ciger, A.; Saygi, S.; Renda, Y.; Yalaz, K. Atypical EEG findings in subacute sclerosing panencephalitis. Clin Electroencephalogr. 1995, 26, 193–199.
96. Bohlega, S.; al-Kawi, M.Z. Subacute sclerosing panencephalitis. Imaging and clinical correlation. J Neuroimaging. 1994, 4, 71–76.
97. Brismar, J.; Gascon, G.G.; von Steyern, K.V.; Bohlega, S. Subacute sclerosing panencephalitis: evaluation with CT and MR. Am J Neuroradiol. 1996, 17, 761–772.
98. Reiber, H.; Lange, P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem. 1991, 37, 1153–1160.
99. Dörries, R.; ter Meulen, V. Detection and identification of virus-specific, oligoclonal IgG in unconcentrated cerebrospinal fluid by immunoblot technique. J Neuroimmunol. 1984, 7, 77–89.
100. Pohl-Koppe, A.; Kaiser, R.; ter Meulen, V.; Liebert, U.G. Antibody reactivity to individual structural proteins of measles virus in the CSF of SSPE and MS patients. Clin Diagn Virol. 1995, 4, 135–147.
101. Felgenhauer, K.; Reiber, H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Invest. 1992, 70, 28–37.
102. Taylor, W.J.; DuRant, R.H.; Dyken, P.R. Treatment of subacute sclerosing panencephalitis: an overview. Drug Intell Clin Pharm. 1984, 18, 375–381.
103. Haslam, R.H.; McQuillen, M.P.; Clark, D.B. Amantadine therapy in subacute sclerosing panencephalitis. A preliminary report. Neurology. 1969, 19, 1080–1086.
104. Robertson, W.C., Jr.; Clark, D.B.; Markesbery, W.R. Review of 38 cases of subacute sclerosing panencephalitis: effect of amantadine on the natural course of the disease. Ann Neurol. 1980, 8, 422–425.
105. Gadoth, N.; Kott, E.; Levin, S.; Hahn, T. The interferon system in subacute sclerosing panencephalitis and its response to isoprinosine. Brain Dev. 1989, 11, 308–312.
106. Dyken, P.R.; Swift, A.; DuRant, R.H. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann Neurol. 1982, 11, 359–364.
107. Jones, C.E.; Dyken, P.R.; Huttenlocher, P.R.; Jabbour, J.T.; Maxwell, K.W. Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients. Lancet. 1982, 1, 1034–1037.
108. Fukuyama, Y.; Nihei, K.; Matsumoto, S.; Ebina, T.; Kamoshita, S.; Sato, T.; Arima, M.; Yabuuchi, H.; Ueda, S.; Ohtahara, S. Clinical effects of MND-19 (inosiplex) on subacute sclerosing panencephalitis—a multi-institutional collaborative study—The Inosiplex-SSPE Research Committee. Brain Dev. 1987, 9, 270–282.
109. Huttenlocher, P.R.; Mattson, R.H. Isoprinosine in subacute sclerosing panencephalitis. Neurology. 1979, 29, 763–771.
110. DuRant, R.H.; Dyken, P.R.; Swift, A.V. The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis. J Pediatr. 1982, 101, 288–293.
111. DuRant, R.H.; Dyken, P.R. The effect of inosiplex on the survival of subacute sclerosing panencephalitis. Neurology. 1983, 33, 1053–1055.
112. Bye, A.; Balkwill, F.; Brigden, D.; Wilson, J. Use of interferon in the management of patients with subacute sclerosing panencephalitis. Dev Med Child Neurol. 1985, 27, 170–175.
113. Huttenlocher, P.R.; Picchietti, D.L.; Roos, R.P.; Cashman, N.R.; Horowitz, B.; Horowitz, M.S. Intrathecal interferon in subacute sclerosing panencephalitis. Ann Neurol. 1986, 19, 303–305.
114. Panitch, H.S.; Gomez-Plascencia, J.; Norris, F.H.; Cantell, K.; Smith, R.A. Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon. Neurology. 1986, 36, 562–566.
115. Yalaz, K.; Anlar, B.; Oktem, F.; Aysun, S.; Ustacelebi, S.; Gurcay, O.; Gucuyener, K.; Renda, Y. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology. 1992, 42, 488–491.
116. Anlar, B.; Yalaz, K.; Oktem, F.; Kose, G. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Neurology. 1997, 48, 526–528.
117. Cianchetti, C.; Marrosu, M.G.; Muntoni, F.; Fratta, A.; Zuddas, A. Intraventricular alphainterferon in subacute sclerosing panencephalitis. Neurology. 1998, 50, 315–316.
118. Gascon, G.G.; Anlar, B.A.; Fojas, M.; Udani, V. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular alpha interferon in subacute sclerosing panencephalitis (SSPE) [abstract FO-14-5]. Brain Dev. 2002, 24, 409.
119. Takahashi, T.; Hosoya, M.; Kimura, K.; Ohno, K.; Mori, S.; Takahashi, K.; Shigeta, S. The cooperative effect of interferon-alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antiviral Res. 1998, 37, 29–35.
120. Tomoda, A.; Shiraishi, S.; Hosoya, M.; Hamada, A.; Miike, T. Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis. Pediatr Neurol. 2001, 24, 54–59.
121. Solomon, T.; Hart, C.A.; Vinjamuri, S.; Beeching, N.J.; Malucci, C.; Humphery, P. Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavirin and inosiplex. J Child Neurol. 2002, 9, 703–705.
122. Takashima, H.; Eriguchi, M.; Nakamura, T.; Satoh, J.; Kuroda, Y.; Udono, H.; Uchino, A. Interferon therapy-responsive brain metabolic abnormalities in a case of adult-onset subacute sclerosing panencephalitis evaluated by 1H MRS analysis. J Neurol Sci. 2003, 207, 59–63.
123. Breitfeld, V.; Hashida, Y.; Sherman, F.E.; Odagiri, K.; Yunis, E.J. Fatal measles infection in children with leukemia. Lab Invest. 1973, 28, 279–291.
124. Mustafa, M.M.; Weitman, S.D.; Winick, N.J.; Bellini, W.J.; Timmons, C.F.; Siegel, J.D. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis. 1993, 16, 654–660.
125. Hughes, I.; Jenney, M.E.; Newton, R.W.; Morris, D.J.; Klapper, P.E. Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1993, 68, 775–778.
126. Chen, R.E.; Ramsay, D.A.; deVeber, L.L.; Assis, L.J.; Levin, S.D. Immunosuppressive measles encephalitis. Pediatr Neurol. 1994, 10, 325–327.
127. Vigliano, P.; Boffi, P.; Giordana, M.T.; Tovo, P.A.; Palomba, E.; Rigardetto, R. Subacute measles encephalitis in a boy with perinatal HIV-1 infection. Dev Med Child Neurol. 1995, 37, 1117–1119.
128. Budka, H.; Urbanits, S.; Liberski, P.P.; Eichinger, S.; Popow-Kraupp, T. Subacute measles virus encephalitis: a new and fatal opportunistic infection in a patient with AIDS. Neurology. 1996, 46, 586–587.
129. Poon, T.P.; Tchertkoff, V.; Win, H. Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy. A case report. Acta Cytol. 1998, 42, 729–733.
130. Bitnun, A.; Shannon, P.; Durward, A.; Rota, P.A.; Bellini, W.J.; Graham, C.; Wang, E.; Ford- Jones, E.L.; Cox, P.; Becker, L.; Fearon, M.; Petric, M.; Tellier, R. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis. 1999, 29, 855–861.
131. Gazzola, P.; Cocito, L.; Capello, E.; Roccatagliata, L.; Canepa, M.; Mancardi, G.L. Subacute measles encephalitis in a young man immunosuppressed for ankylosing spondylitis. Neurology. 1999, 52, 1074–1077.
132. Baczko, K.; Liebert, U.G.; Cattaneo, R.; Billeter, M.A.; Roos, R.P.; ter Meulen, V. Restriction of measles virus gene expression in measles inclusion body encephalitis. J Infect Dis. 1988, 158, 144–150.
133. Barthez Carpentier, M.A.; Billard, C.; Maheut, J.; Jourdan, M.L.; Degenne, D.; Ruchoux, M.M.; Goudeau, A.; Santini, J.J. Acute measles encephalitis of the delayed type: neuroradiological and immunological findings. Eur Neurol. 1992, 32, 235–237.
134. Olding-Stenkvist, E.; Forsgren, M.; Henley, D.; Kreuger, A.; Lundmark, K.M.; Nilsson, A.; Wadell, G. Measles encephalopathy during immunosuppression: failure of interferon treatment. Scand J Infect Dis. 1982, 14, 1–4.
135. Simpson, R.; Eden, O.B. Possible interferon response in a child with measles encephalitis during immunosuppression. Scand J Infect Dis. 1984, 16, 315–319.
136. ter Meulen, V.; Katz, M. The proposed viral etiology of multiple sclerosis and related demyelinating diseases. In; Raine, C.S., McFarland, H.F., Tourtellotte, W.W., Eds. Multiple Sclerosis. Clinical and Pathogenetic Basis; Chapman and Hall: London, 1997, 287–305.
137. Adams, J.M.; Imagawa, D.T. Measles antibodies in multiple sclerosis. Proc Soc Exp Biol Med. 1962, 111, 562–566.
138. Johnson, R.T. The possible viral etiology of multiple sclerosis. Adv Neurol. 1975, 13, 1–46.
139. Norrby, E. Viral antibodies in multiple sclerosis. Prog Med Virol. 1978, 24, 1–39.
140. Haase, A.T.; Ventura, P.; Gibbs, C.J.J.; Tourtellotte, W.W. Measles virus nucleotide sequences: detection by hybridization in situ. Science. 1981, 212, 672–675.
141. Cosby, S.L.; McQuaid, S.; Taylor, M.J.; Bailey, M.; Rima, B.K.; Martin, S.J.; Allen, I.V. Examination of eight cases of multiple sclerosis and 56 neurological and non-neurological controls for genomic sequences of measles virus, canine distemper virus, simian virus 5 and rubella virus. J Gen Virol. 1989, 70, 2027–2036.
142. Stevens, J.G.; Bastone, V.B.; Ellison, G.W.; Myers, L.W. No measles virus genetic information detected in multiple sclerosis–derived brains. Ann Neurol. 1980, 8, 625–627.
143. Hall, W.W.; Choppin, P.W. Failure to detect measles virus proteins in brain tissue of patients with multiple sclerosis. Lancet. 1982, 1, 957.
144. Godec, M.S.; Asher, D.M.; Murray, R.S.; Shin, M.L.; Greenham, L.W.; Gibbs, C.J., Jr; Gajdusek, D.C. Absence of measles, mumps, and rubella viral genomic sequences from multiple sclerosis brain tissue by polymerase chain reaction. Ann Neurol. 1992, 32, 401–404.
145. Tamashiro, V.G.; Perez, H.H.; Griffin, D.E. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr Infect Dis J. 1987, 6, 451–454.
146. Hirsch, R.L.; Griffin, D.E.; Johnson, R.T.; Cooper, S.J.; Lindo de Soriano, I.; Roedenbeck, S.; Vaisberg, A. Cellular immune responses during complicated and uncomplicated measles virus infections of man. Clin Immunol Immunopathol. 1984, 31, 1–12.